Skip to main content
. 2020 Jul 21;11(9):2561–2569. doi: 10.1111/1759-7714.13574

Table 1.

Characteristics of DLL3‐positive and DLL3‐negative pulmonary LCNEC patients

Factor DLL3‐positive (n = 26) DLL3‐negative (n = 44) P‐value
Mean age, range (years) 65.6 (50–78) 71.1 (45–84) <0.01
Sex
Male 21 (81%) 39 (89%) 0.37
Female 5 (19%) 5 (11%)
Smoking status
Former or current 24 (92%) 41 (93%) 0.49
Never smoked 2 (8%) 3 (7%)
Lung function
Mean FEV1.0% 74.0% 66.6% <0.01
Surgical procedure
Lobectomy 22 (85%) 34 (77%) 0.45
Sublobar resection 4 (15%) 10 (23%)
Adjuvant chemotherapy
Performed 12 (46%) 11 (25%) 0.07
Pure or combined
Pure LCNEC 26 (100%) 39 (89%) 0.07
Combined LCNEC 0 (0%) 5 (11%)
Pathological stage
IA 5 (19%) 16 (36%) 0.11
IB 10 (38%) 10 (22%)
IIA 4 (15%) 5 (11%)
IIB 0 (0%) 6 (14%)
IIIA 6 (23%) 7 (16%)
IIIB 1 (4%) 0 (0%)
Pathological tumor size (mm)
Mean 38.2 35.6 0.59
Lymph node metastasis
pN 0 18 (69%) 33 (75%) 0.60
pN 1–2 8 (31%) 11 (25%)
Pleural invasion
(−) 14 (54%) 27 (61%) 0.54
(+) 12 (46%) 17 (39%)
Vascular invasion
(−) 5 (19%) 15 (34%) 0.18
(+) 21 (81%) 29 (66%)
Lymphatic permeation
(−) 4 (15%) 22 (50%) <0.01
(+) 22 (85%) 22 (50%)